文献速递骨显像与常规 SPECT核素与放射性配体治疗

转移性去势抵抗性前列腺癌患者接受镭-223治疗前定量骨SPECT/CT的预后价值

The Prognostic Value of Quantitative Bone SPECT/CT Before 223Ra Treatment in Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2020-05-22

本研究前瞻性纳入60例转移性去势抵抗性前列腺癌(mCRPC)患者,在首次镭-223(223Ra)治疗前行99mTc-DPD骨SPECT/CT定量分析,比较摄取值与治疗完成可行性及总生存(OS)的关系。结果显示,因进展和/或血细胞减少未能完成223Ra治疗者骨摄取显著更高(31.9 vs 25.4 %ID,P<0.02),骨摄取≥26 %ID者OS缩短至7.3个月,低于26 %ID者为30.8个月(P=0.008);%ID/L为OS独立预后因素(HR 1.381/单位)。

要点

  • 基线定量骨SPECT/CT骨摄取高者更可能因进展和/或血细胞减少无法完成223Ra治疗。
  • 骨摄取≥26 %ID者中位OS为7.3个月,低于26 %ID者为30.8个月(P=0.008)。
  • %ID/L为OS独立预后因素(HR 1.381/单位),SUVmax与生存不相关。

核心结论

  • 基线定量骨SPECT/CT对接受223Ra治疗的mCRPC患者具有生存预后价值。

研究设计与样本

  • 前瞻性纳入60例连续mCRPC患者,在首次223Ra治疗前行覆盖颅骨至股骨中段的中轴骨SPECT/CT。
  • 骨分区由低剂量CT定义,发射数据经散射、衰减和衰变校正并辅以分辨率恢复。
  • 采用Kaplan-Meier估计、U检验和Cox回归分析进行统计。

主要发现

  • 中轴骨总99mTc-DPD摄取范围为11%至56%注射剂量(%ID)或1.8至10.5 %ID/1000 mL骨体积(%ID/L)。
  • SUVmean范围为1.9至7.4,SUVmax范围为18至248。
  • 因进展和/或血细胞减少未能完成223Ra治疗者(n=23)骨摄取显著更高(31.9 vs 25.4 %ID,6.0 vs 4.7 %ID/L;P<0.02)。
  • 223Ra治疗后中位OS为15.2个月;骨摄取≥26 %ID者OS缩短至7.3个月,低于26 %ID者为30.8个月(P=0.008)。
  • %ID/L和SUVmean获得相似结果;SUVmax与生存不相关;%ID/L为OS独立预后因素(HR 1.381/单位),与既往治疗线数并列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiolabeled bisphosphonates such as 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) typically show intense uptake in skeletal metastases from metastatic castration-resistant prostate cancer (mCRPC). Extensive bone involvement is regarded as a risk factor for mCRPC patients treated with 223Ra-dichloride (223Ra). The aim of this study was to quantify 99mTc-DPD uptake by means of SPECT/CT before 223Ra and compare the results with the feasibility of treatment and overall survival (OS). Methods: Sixty consecutive mCRPC patients were prospectively included in this study. SPECT/CT of the central skeleton covering the skull to the mid-femoral level was performed before the first cycle of 223Ra. The bone compartment was defined by means of low-dose CT. Emission data were corrected for scatter, attenuation, and decay supplemented by resolution recovery using dedicated software. The Kaplan-Meier estimator, U test, and Cox regression analysis were used for statistics. Results: Total 99mTc-DPD uptake of the central skeleton varied between 11% and 56% of injected dose (%ID) or between 1.8 and 10.5 %ID/1,000 mL of bone volume (%ID/L). SUVmean ranged from 1.9 to 7.4, whereas the SUVmax range was 18-248. Patients unable to complete 223Ra treatment because of progression and/or cytopenia (n = 23) showed significantly higher uptake (31.9 vs. 25.4 %ID and 6.0 vs. 4.7 %ID/L; P < 0.02). OS after 223Ra (median, 15.2 mo) was reduced to 7.3 mo in cases of skeletal uptake that was 26 %ID or higher, as compared with 30.8 mo if lower than 26 %ID (P = 0.008). Similar results were obtained for %ID/L and SUVmean SUVmax did not correlate with survival. %ID/L was identified as an independent prognostic factor for OS (hazard ratio, 1.381 per unit), along with number of previous treatment lines. Conclusion: Quantitative SPECT/CT of bone scans performed at baseline is prognostic for survival in mCRPC patients treated with 223Ra.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dittmann H, Kaltenbach S, Weissinger M, et al. The Prognostic Value of Quantitative Bone SPECT/CT Before 223Ra Treatment in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2020. PMID: 32444369. doi:10.2967/jnumed.119.240408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。